

Trimethylsilyltriflate-Promoted Addition of 2-Trimethylsilyloxyfuran to a Chiral Cyclic Nitron; a Short Synthesis of [1*S*(1 α ,2 β ,7 β ,8 α ,8 $\alpha\alpha$)]-1,2-Di(*t*-butyldiphenylsilyloxy)-indolizidine-7,8-diol

Marco Lombardo* and Claudio Trombini*

Dipartimento di Chimica 'G. Ciamician', Università di Bologna, via Selmi 2, I-40126 Bologna, Italy

Received 7 September 1999; revised 15 October 1999; accepted 4 November 1999

Abstract—The trimethylsilyl triflate promoted addition of 2-trimethylsilyloxyfuran to (3*S*,4*S*)-3,4-dihydro-3,4-di(*t*-butyldiphenylsilyloxy)-2*H*-pyrrole 1-oxide, derived from (*R,R*)-tartaric acid, displays complete facial selectivity, affording two diastereomeric butenolides in excellent overall yield. The major adduct undergoes silica-gel induced ring-closure to give in almost quantitative yield [4*S*(4 α ,5 β ,5 $\alpha\beta$,5- $\beta\alpha$,8 $\alpha\alpha$)]-hexahydro-4,5-di(*t*-butyldiphenylsilyloxy)-pyrrolo [1,2-*b*]furo[2,3-*d*] isoxazol-7(3*H*)one; reduction with DIBAH followed by hydrogenolysis on Pd(OH)₂/C affords the partially protected 1,2,7,8-indolizidinetetrol. © 1999 Elsevier Science Ltd. All rights reserved.

Glycosidases and glycosyltransferases are widespread enzymes present in almost all organisms. They are essential for the processing of oligo- and polysaccharides and complex carbohydrates such as glycolipids and glycoproteins.¹ The inhibition of this family of hydrolases represents a powerful solution on the one hand to control obesity, diabetes and other metabolic disorders,² and on the other hand to block infection, inflammation and metastasis by preventing the biogenesis of membrane glycoproteins in fungi, bacteria and viruses.³ A number of polyhydroxylated piperidines, pyrrolidines, indolizidines and pyrrolizidines, isolated from natural sources, are powerful and specific inhibitors of α - and β -glycosidases, and an even larger number of isomers and congeners have been synthesised and assayed for biological activity. A few of them display outstanding inhibition levels.⁴ Among polyhydroxylated indolizidine alkaloids, besides naturally occurring lentiginosine, swainsonine and castanospermine (Fig. 1), a number of stereoisomers and analogues have been synthesised and tested in order to get information on structure–activity relationships.⁵ For example, among 1,2,7,8-indolizidinetetrols, the stereoisomers **1a**,⁶ **1b**⁷ and **1c**⁷ have been synthesised and tested for biological activity.

Here we propose a route to the skeleton of [1*S*(1 α ,2 β ,7 β ,8 α ,8 $\alpha\alpha$)]-1,2,7,8-indolizidinetetrol (**1d**) and of *ent*-**1d** by applying to a chiral cyclic five-membered ring nitron deriving from tartaric acid, an efficient protocol previously developed by us for the synthesis of 2-substituted 3,4-piperidinediols starting from aldonitrones (Scheme 1).⁸

The key reaction is the trimethylsilyl triflate (TMSOTf)-catalysed condensation of 2-trimethylsilyloxyfuran with an aldonitron **2** to give an intermediate butenolide **3**, which, in the presence of fluoride, undergoes cyclisation to **4**.⁹ These bicyclic compounds are successfully transformed into piperidines **6** in a two-reductive step sequence involving DIBAH reduction to lactol **5** and, finally, hydrogenolysis to the target piperidine.⁸

Five-membered cyclic nitrones derived from tartaric acid¹⁰ have been successfully manipulated to indolizidines by Brandi¹¹ and Wightman¹² exploiting 1,3-dipolar cycloaddition reactions. The results obtained by applying our preceding protocol to nitron **2a** are summarised in Scheme 2.

Condensation of **2a** and 2-trimethylsilyloxyfuran in the presence of TMSOTf (10%) in dichloromethane at –20°C displayed complete facial selectivity and afforded butenolides **3a** and **3b** possessing the 2'*S*,5*S* and 2'*S*,5*R* absolute stereochemistry, respectively, in 82/18 ratio and in 71% overall yield. Bulky *t*-butyldiphenylsilyl protecting group (TBDPS) in **2a** proved to be an optimum choice forcing the nucleophilic attack of 2-trimethylsilyloxyfuran only on

Keywords: 2-trimethylsilyloxyfuran; (3*S*,4*S*)-3,4-dihydro-3,4-di(*t*-butyldiphenylsilyloxy)-2*H*-pyrrole 1-oxide; [4*S*(4 α ,5 β ,5 $\alpha\beta$,5 $\beta\alpha$,8 $\alpha\alpha$)]-hexahydro-4,5-di(*t*-butyldiphenylsilyloxy)-pyrrolo [1,2-*b*]furo[2,3-*d*] isoxazol-7(3*H*)one.

* Corresponding authors. Tel.: +51-2099513; fax: +51-2099456; e-mail: marlom@ciam.unibo.it; trombini@ciam.unibo.it






Figure 1.



Scheme 1.



Scheme 2.




Figure 2.

the less encumbered *si* face of the nitron **2a**. Formation of the 2'*S*,5*S* relationship is favoured (d.e. 64%) according to synclinal approach **A** in Fig. 2, which involves the *re* face of 2-trimethylsilyloxyfuran. Anti approach **B** is disfavoured both by unfavourable dipolar interactions and by oxygen atoms lone pairs repulsion. Butenolides **3a** and **3b** were easily separated by silica-gel flash-chromatography and treated with diluted trifluoroacetic acid (TFA) in order to remove the trimethylsilyl group chemoselectively. Silica-gel chromatographic purification of the crude residue led, in one case, to complete cyclisation to **4a**, as we observed previously on simple aldonitrones,^{9a} in the other case to the almost quantitative recovery of **7b**. The absence of the corresponding tricyclic product deriving from **3b** was probably due to steric compression in the *cis-syn-cis* triquinane-type nucleus. Such a dramatically different behaviour allowed us to develop a shorter and more efficient procedure for the synthesis of **4a**; after condensation of 2-trimethylsilyloxyfuran with **2a**, the crude reaction mixture was directly treated with dilute aqueous TFA, then, after water extraction and solvent concentration, the residue was eluted through a silica-gel column affording **4a** (56%) and **7b** (12%).

Transformation of the hexahydropyrrolo[1,2-*b*]furo[2,3-*d*]-isoxazol-7(3H)one ring system of **4a** into an indolizidine was easily accomplished via DIBAH reduction of **4a** to **5a** followed by hydrogenolysis of **5a** in the presence of Pd(OH)₂. The N–O bond cleavage was followed by spontaneous intramolecular reductive amination to [1*S*(1 α ,2 β ,7 β ,8 α ,8 α)]-1,2-di(*t*-butyldiphenylsilyloxy)-indolizidine-7,8-diol (**6a**).

Regioselectively protected **6a** offers interesting opportunities since it allows the hydroxyl groups to be orthogonally manipulated to generate further stereoisomers.

Experimental

General

^1H NMR and ^{13}C NMR spectra in deuterated solvents were recorded at 300 and 75 MHz, respectively, using a Varian Gemini 300 spectrometer. Chemical shifts are reported in ppm relative to internal standard Me_4Si . Optical rotations were measured on a Perkin–Elmer 241 polarimeter. Water content of anhydrous solvents used was measured with a Karl-Fisher titrator Mettler DL18. Reactions were performed in oven-dried glassware under argon. Hydrogenations were performed at 45 psi on a Parr apparatus. 2-Trimethylsilyloxyfuran and moist 20% $\text{Pd}(\text{OH})_2$ on carbon (Degussa type E101) were purchased from Aldrich. Nitrone **2a** was synthesised from (*R,R*)-tartaric acid diethyl ester according to the procedure reported by Brandi et al.¹¹ Melting points are uncorrected.

5-[1'-Trimethylsilyloxy-3',4'-di(*t*-butyldiphenylsilyloxy)-2'-pyrrolidinyl]-2(5H)-furanones (3a, 3b). 2-Trimethylsilyloxyfuran (0.19 mL, 1.1 mmol) was added to a solution of **2a** (0.6 g, 1 mmol) in CH_2Cl_2 (2 mL) and the solution was cooled to -20°C . TMSOTf (0.018 mL, 0.1 mmol) was added and the reaction mixture was stirred at -20°C for 1.5 h. The reaction was quenched with aq. NaHCO_3 and extracted with CH_2Cl_2 (3 \times 5 mL). Silica gel was directly added to the combined organic layers and the solvent was evaporated at reduced pressure. The solid residue was loaded on a silica gel column. Elution with cyclohexane/ethyl acetate (95/5) afforded 0.43 g (58%) of **3a** as a white solid and 0.1 g (13%) of **3b** as an oil.

[2'S-[2' α ,3' α ,4' β (5R*)]-3a: m.p. 98–100 $^\circ\text{C}$; $[\alpha]_{\text{D}}^{22} = -11.0$ ($c=0.21$ in CHCl_3); ^1H NMR (CDCl_3) δ 0.07 (s, 9H, SiMe_3), 0.93 (s, 9H, $\text{Si}t\text{Bu}$), 0.97 (s, 9H, $\text{Si}t\text{Bu}$), 2.95 (dd, $J=4.2/11.0$ Hz, 1H, H-5'), 3.01 (br d, $J=11.0$ Hz, 1H, H-5'), 3.19 (br dd, $J\approx 1.5/6.0$ Hz, 1H, H-2'), 4.20–4.30 (m, 2H, H-3'+H-4'), 4.99 (dt, $J=2.0/6.0$ Hz, 1H, H-5), 5.87 (dd, $J=2.0/5.5$ Hz, 1H, H-3), 7.20–7.62 (m, 21H, ArH+H-4); ^{13}C NMR (CDCl_3) δ -0.3 (SiCH_3), 19.0 (SiCMe_3), 19.1 (SiCMe_3), 26.7 (SiCMe_3), 26.8 (SiCMe_3), 64.8 (C-5'), 78.4, 78.9, 79.5, 81.9 (C-5, C-2', C-3', C-4'), 121.7 (C-3), 127.6, 127.7, 128.0, 129.6, 129.7, 129.8, 129.9, 132.8 (Cquat), 133.0 (Cquat), 133.1 (Cquat), 133.6 (Cquat), 135.7, 135.8, 154.7 (C-4), 172.6 (C=O). Anal. Calcd. for $\text{C}_{43}\text{H}_{55}\text{NO}_5\text{Si}_3$: C, 68.85; H, 7.39; N, 1.87. Found: C, 68.53; H, 7.42; N, 1.85.

[2'S-[2' α ,3' α ,4' β (5S*)]-3b: $[\alpha]_{\text{D}}^{22} = +2.0$ ($c=0.11$ in CHCl_3); ^1H NMR (CDCl_3) δ 0.13 (s, 9H, SiMe_3), 0.87 (s, 9H, $\text{Si}t\text{Bu}$), 0.97 (s, 9H, $\text{Si}t\text{Bu}$), 2.99–3.03 (m, 2H, H-5'), 3.58–3.64 (m, 1H, H-2'), 3.80–3.97 (m, 1H, CHOSi), 4.02–4.08 (m, 1H, CHOSi), 5.06 (dt, $J=2.0/5.1$ Hz, 1H, H-5), 5.92 (dd, $J=2.0/7.8$ Hz, 1H, H-3), 7.10–7.70 (m, 21H, ArH+H-4); ^{13}C NMR (CDCl_3) δ -0.17 (SiCH_3), 19.0 (SiCMe_3), 19.1 (SiCMe_3), 26.8 (SiCMe_3), 63.7 (C-5'), 77.6, 77.9, 78.1, 82.1 (C-5, C-2', C-3', C-4'), 122.0 (C-3), 127.7, 127.9, 129.6, 129.8, 129.9, 132.1, 132.2, 133.2, 133.9, 135.5, 135.7, 135.9, 155.5 (C-4), 172.5 (C=O). Anal. Calcd. for $\text{C}_{43}\text{H}_{55}\text{NO}_5\text{Si}_3$: C, 68.85; H, 7.39; N, 1.87. Found: C, 68.66; H, 7.44; N, 1.83.

[4S(4 α ,5 β ,5 $\alpha\beta$,5 $\beta\alpha$,8 $\alpha\alpha$)]-Hexahydro-4,5-di(*t*-butyldiphenylsilyloxy)-pyrrolo[1,2-*b*]furo[2,3-*d*] isoxazol-7(3H)one (4a). 0.65 M Trifluoroacetic acid in H_2O (0.23 mL, 0.15 mmol) was added to a solution of **3a** (0.18 g, 0.23 mmol) in CH_2Cl_2 (2 mL). The reaction mixture was stirred at room temperature for 45 min, then quenched with aq. NaHCO_3 and extracted with CH_2Cl_2 (3 \times 5 mL). The combined organic layers were dried (Na_2SO_4) and solvent was evaporated to dryness. Chromatography of the residue on silica gel using cyclohexane/ethyl acetate (95/5) yielded 0.144 g (92%) of pure **4a**: $[\alpha]_{\text{D}}^{22} = +46.0$ ($c=0.20$ in CHCl_3); ^1H NMR (CDCl_3) δ 0.93 (s, 9H, $\text{Si}t\text{Bu}$), 0.96 (s, 9H, $\text{Si}t\text{Bu}$), 2.58 (dd, $J=4.8/18.6$ Hz, 1H, H-8), 2.66 (br dd, $J\approx 0.9/18.6$ Hz, 1H, H-8), 3.11 (br dd, $J\approx 0.6/14.7$ Hz, 1H, H-3), 3.66 (dd, $J=4.2/14.7$ Hz, 1H, H-3), 3.86 (br s, 1H, H-5a), 4.22–4.28 (m, 2H, H-4+H-5), 4.77 (br dd, $J\approx 1.6/4.5$ Hz, 1H, H-5b), 4.92 (m, 1H, H-8a; upon irradiation of H-8 the signal collapses into a doublet with $J=4.5$ Hz), 7.22–7.58 (m, 20H, ArH); ^{13}C NMR (CDCl_3) δ 14.2 (C-8), 19.1 (SiCMe_3), 26.8 (SiCMe_3), 27.0 (SiCMe_3), 34.0 (C-3), 63.9 (C-5a), 78.2, 78.3, 79.1, 81.3, (C-4, C-5, C-5b, C-8a), 127.8, 127.9, 128.0, 130.0 (Cquat), 130.2 (Cquat), 131.9 (Cquat), 132.3 (Cquat), 135.5, 135.6, 173.5 (C=O). Anal. Calcd. for $\text{C}_{40}\text{H}_{47}\text{NO}_5\text{Si}_2$: C, 70.86; H, 6.99; N, 2.07. Found: C, 70.95; H, 6.91; N, 2.16.

H-5a/H-5b *trans* and a H-5a/H-5 *trans* stereorelationships were assigned on the basis of n.O.e. measurements. Upon irradiation of H-5a, similar enhancements for both H-5b (3.0%) and H-5 (4.6%) were observed; moreover, irradiation of H-5b caused a strong enhancement of H-5 (10.5%) and a smaller response of H-5a (4.7%).

[2',S-[2' α ,3' α ,4' β (5S*)]-5-[1'-Hydroxy-3',4'-di(*t*-butyldiphenylsilyloxy)-2'-pyrrolidinyl]-2(5H)-furanone (7b). TFA treatment of **3b** followed by silica gel chromatography brought about the chemoselective deprotection of the trimethylsilyl group affording **7b** in almost quantitative yield. $[\alpha]_{\text{D}}^{22} = +21.9$ ($c=0.62$ in CHCl_3); ^1H NMR (CDCl_3) δ 0.93 (s, 9H, $\text{Si}t\text{Bu}$), 0.97 (s, 9H, $\text{Si}t\text{Bu}$), 3.12 (dd, $J=3.6/10.5$ Hz, 1H, H-5'), 3.16–3.26 (m, 2H, H-5'+H-2'), 3.98–4.05 (m, 1H, H-4'), 4.20 (dd, $J=1.5/3.0$ Hz, 1H, H-3'), 4.83 (ddd, $J=1.5/2.1/6.6$ Hz, 1H, H-5), 5.86 (dd, $J=2.1/5.7$ Hz, 1H, H-3), 6.81 (dd, $J=1.5/5.7$ Hz, 1H, H-4), 7.20–7.70 (m, 20H, ArH); ^{13}C NMR (CDCl_3) δ 19.0 (SiCMe_3), 19.1 (SiCMe_3), 26.8 (SiCMe_3), 62.8 (C-5'), 77.8, 78.4, 78.8, 83.1 (C-5, C-2', C-3', C-4'), 121.8 (C-3), 127.6, 127.7, 127.8, 127.9, 129.8, 129.9, 130.0, 132.6 (Cquat), 132.7 (Cquat), 132.9 (Cquat), 133.4 (Cquat), 135.58, 135.63, 135.9, 154.2 (C-4), 172.7 (C=O). Anal. Calcd. for $\text{C}_{40}\text{H}_{47}\text{NO}_5\text{Si}_2$: C, 70.86; H, 6.99; N, 2.07. Found: C, 70.94; H, 7.10; N, 2.11.

[1S(1 α ,2 β ,7 β ,8 α ,8 $\alpha\alpha$)]-1,2-di(*t*-butyldiphenylsilyloxy)-indolizidine-7,8-diol (6a). 1 M DIBAH in hexane (0.55 mL, 0.55 mmol) was added dropwise at -78°C to a solution of **4a** (0.24 g, 0.35 mmol) in anhydrous diethyl ether (8 mL). The reaction mixture was stirred for 4 h at -78°C and then quenched with ice. Seignette salt was added in order to dissolve aluminum salts and, after stirring for 1 h, the solution was carefully extracted with Et_2O . The combined organic layers were dried (Na_2SO_4) and evaporated under reduced pressure. The residue was filtered

affording 0.16 g (67%) of crude **5a** as a mixture of epimers at C-7: $^1\text{H NMR}$ (CDCl_3) two broad triplets at δ 5.63 and δ 4.90 with $J \approx 4.0$ Hz, due to H-7; $^{13}\text{C NMR}$ (CDCl_3) δ 89.9 and 98.9 (C-7).

Crude lactol **5a** (0.16 g, 0.24 mmol) and 20% $\text{Pd}(\text{OH})_2$ on carbon (0.035 g) in anhydrous methanol (10 mL) was hydrogenated for 12 h at 45 psi. The solution was filtered over Celite and the solvent was removed at reduced pressure. The residue was purified by flash-chromatography on silica gel using cyclohexane/ethyl acetate (95/5) yielding **6a** (0.106 g, 66%) as a viscous oil: $[\alpha]_{\text{D}}^{22} = +8.4$ ($c = 0.62$ in CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 0.89 (s, 9H, Si*t*Bu), 1.06 (s, 9H, Si*t*Bu), 1.61 (br dq, $J \approx 5.1/12.6$ Hz, 1H, H-6), 1.78–1.86 (m, 1H, H-6), 1.97–2.11 (m, 2H, H-5+H-8a), 2.18 (dd, $J = 5.4/9.9$ Hz, 1H, H-3), 2.56–2.62 (m, 1H, H-5), 2.63 (d, $J = 9.9$ Hz, 1H, H-3), 3.24–3.35 (m, 2H, H-7+H-8), 4.29 (d, $J = 5.1$ Hz, 1H, CHOSi), 4.39 (d, $J = 5.1$ Hz, 1H, CHOSi), 7.27–7.78 (m, 20H, ArH); $^{13}\text{C NMR}$ (CDCl_3 , APT) δ 19.1 (SiCMe₃), 19.2 (SiCMe₃), 26.7 (SiCMe₃), 27.0 (SiCMe₃), 31.0 (C-6), 47.9 (C-5), 59.0 (C-3), 73.5, 74.8, 76.4, 81.0, 85.8, (C-1, C-2, C-7, C-8, C-8a), 127.2, 127.5, 127.6, 127.7, 129.3, 129.5, 129.7, 129.8, 133.4 (Cquat), 133.5 (Cquat), 133.6 (Cquat), 134.7 (Cquat), 135.6, 135.9. Anal. Calcd. for C₄₀H₅₁NO₄Si₂: C, 72.14; H, 7.72; N, 2.10. Found: C, 72.18; H, 7.65; N, 2.13.

Acknowledgements

The authors thank M.U.R.S.T.—Rome (National Project ‘Stereoselezione in Sintesi Organica. Metodologie e Applicazioni’) and University of Bologna (funds for selected topics) for financial support.

References

- Elbein, A. D. In *Comprehensive Medicinal Chemistry*, Sammes, P. G. Ed.; Pergamon: New York, 1990; 2, pp 365–381.
- Robinson, K. M.; Begovic, M. E.; Rhinehart, B. L.; Heineke, E. W.; Ducep, J.-B.; Kastner, P. R.; Marshall, F. N.; Danzin, C. *Diabetes* **1991**, *40*, 825.
- (a) Elbein, A. D. *Ann. Rev. Biochem.* **1987**, *56*, 497. (b) Taylor, D. L.; Nash, R.; Fellows, L. E.; Kang, M. S.; Tyms, A. S. *Antiviral Chem. Chemother.* **1992**, *3*, 273. (c) Taylor, D. L.; Kang, M. S.; Brennan, T. M.; Bridges, C. G.; Sunkara, P. S.; Tyms, A. S. *Antimicrob. Agents Chemother.* **1994**, *38*, 1780. (d) Gross, P. E.; Baker, M. A.; Carver, J. P.; Dennis, J. W. *Clinical Cancer Res.* **1995**, *1*, 935.
- (a) Wong, C.-H.; Halcomb, R. L.; Ichihawa, Y.; Kajimoto, T. *Angew. Chem. Int. Ed. Engl.* **1995**, *34*, 521. (b) Bols, M. *Acc. Chem. Res.* **1998**, *31*, 1.
- (a) Carretero, J. C.; Arrayás, R. G. *J. Org. Chem.* **1998**, *63*, 2993 and references quoted therein. (b) Burgess, K.; Henderson, I. *Tetrahedron* **1992**, *48*, 4045.
- Furieux, R. H.; Gainsford, G. J.; Mason, J. M.; Tyler, P. C.; Hartley, O.; Winchester, B. G. *Tetrahedron* **1995**, *51*, 12611.
- Davis, B.; Bell, A. A.; Nash, R. J.; Watson, A. A.; Griffiths, R. C.; Jones, M. G.; Smith, C.; Fleet, G. W. *J. Tetrahedron Lett.* **1996**, *37*, 8565.
- Degiorgis, F.; Lombardo, M.; Trombini, C. *Synthesis* **1997**, 1243. See also Degiorgis, F.; Lombardo, M.; Trombini, C. *Org. Prep. Proced. Int.* **1997**, *29*, 485.
- (a) Camiletti, C.; Poletti, L.; Trombini, C. *J. Org. Chem.* **1994**, *59*, 6843. (b) Castellari, C.; Lombardo, M.; Pietropaolo, G.; Trombini, C. *Tetrahedron: Asymmetry* **1996**, *7*, 1059. (c) Degiorgis, F.; Lombardo, M.; Trombini, C. *Tetrahedron* **1997**, *53*, 11721.
- (a) Ballini, R.; Marcantoni, E.; Petrini, M. *J. Org. Chem.* **1992**, *57*, 1316. (b) Cicchi, S.; Höld, I.; Brandi, A. *J. Org. Chem.* **1993**, *58*, 527.
- (a) Brandi, A.; Cicchi, S.; Cordero, F. M.; Frignoli, R.; Goti, A.; Picasso, S.; Vogel, P. *J. Org. Chem.* **1995**, *60*, 6806. (b) Goti, A.; Cardona, F.; Brandi, A.; Picasso, S.; Vogel, P. *Tetrahedron: Asymmetry* **1996**, *7*, 1659. (c) Goti, A.; Cardona, F.; Brandi, A. *Synlett* **1996**, 761. (d) Cardona, F.; Valenza, S.; Goti, A.; Brandi, A. *Tetrahedron Lett.* **1997**, *38*, 8097. (e) Cicchi, S.; Numes, Jr., J.; Goti, A.; Brandi, A. *Eur. J. Org. Chem.* **1998**, 419. (f) Cardona, F.; Valenza, S.; Picasso, S.; Goti, A.; Brandi, A. *J. Org. Chem.* **1998**, *63*, 7311.
- (a) McCaig, A. E.; Wightman, R. H. *Tetrahedron Lett.* **1993**, *34*, 3939. (b) McCaig, A. E.; Meldrum, K. P.; Wightman, R. H. *Tetrahedron* **1998**, *54*, 9429.